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Endocrine cut-off criterion
● Regarding wildlife, the new EU pesticide 
regulation 1107/2009 EEC requires: “An 
active substance… shall only be approved 
if,…, it is not considered to have endocrine 
disrupting properties that may cause ad-
verse effects on non-target organisms…“ 
● Thereby, a paradigm shift in regulatory 
decision making  was introduced for this 
specific mode of toxic action: hazard-based 
instead of risk-based.
● Specific scientific criteria for regulatory 
classification of pesticides with endocrine 
disrupting properties are not provided in the 
new regulation (to be proposed by EU 
commission by end of 2013).
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Concentration Addition (CA) 
- general formulation for a n-
compound mixture
Prochloraz Epoxiconazole Flusilazole Propiconazole Triadimenol Difenoconazole Tebuconazole
(Desthio-)
Prothioconazole Cyproconazole Metconazole
Tons sold in 
2009a)
100 - 250 250 - 1000 25 - 100 100- 250 25 - 100 25 – 100 250 - 1000 250 - 1000 10 - 25 25 - 100
Evidence for 
inhibition of 
steroidogenesis
/ aromatase in-
vitrob)
Yes 
(ref. 1 - 10)
Yes 
(ref. 1, 4, 5, 7)
Yes 
(ref. 1, 7)
Yes
(ref. 1, 2, 3, 5, 6, 
7, 9, 11)
Yes
(ref. 1, 3, 6, 7)
Yes 
(ref. 2, 6, 9)
Yes 
(ref. 1, 2, 5, 7)
No
(no data)
Yes 
(ref. 1, 7)
No
(no data)
Potency
aromatase
inhibition in-
vitro (IC50, µM)c)
0.047 1.44 0.055 3.2 12.6 No data 5.8 No data 8.5 No data
Evidence for 
endocrine 
mediated 
(adverse)
effects in-vivo: 
Yes:
testosterone
levels ↓,  ano-
genital distance  
Yes:
disturbed steroid 
hormone balan-
ce, anogenital
Yes:
testosterone and 
estradiol serum
levels ↓, placen-
Yes:
testosterone
levels ↑,  ano-
genital distance  
Yes:
changes in cho-
lesterol levels, 
placental weight
No:
“Information from 
the toxicology 
section gave no 
Yes:
disturbed steroid 
hormone bal-
ance in males, 
(Yes):
ovary weight ↑, 
disruption of 
oestrus cycle,  
(Yes):
litter loss ↑, 
incidences of 
resorptions ↑,  
(Yes):
placental weight 
↑, gestation 
length ↑, post 
Discussion
● There are noticeable differences in endocrine 
hazard profiles of the active substances studied 
which most likely reflect differences in specificity 
and potency (in-vitro data seem to be quite indi-
cative in this respect). 
● Chronic fish studies without endocrine specific 
endpoints and/or poor data quality (i.e. low statis-
tical power to detect effects) hamper final decisi-
ons on the in-vivo relevance of the endocrine 
mechanism(s) suggested by in-vitro results.
● In some cases other than endocrine mediated 
effects may be decisive for the overall hazard 
potential in wildlife.
● This presentation does not anticipate official 
regulatory decisions to be taken in the future.
Ergosterol Biosynthesis Inhibitors 
● Fungicides of world-wide agricultural importance with 
widespread use in major and minor crops.
● Active substances of this heterogeneous chemical 
group (triazoles, imidazoles, pyrimidines) share a 
similar pesticidal mode of action: inhibition of erg-
osterol synthesis in fungi. 
● Intrinsic endocrine hazard potential of EBIs: target 
enzymes in fungi are partly analogous to enzymes 
involved in the production of sex steroid hormones in 
vertebrates (e.g. aromatase). 
● Supposed endocrine mechanism of action of EBIs in 
vertebrates: Disturbance of steroidogenesis.  Asso-
ciated adverse effects: disturbance of sexual de-
velopment (i.e. indirect anti-estrogenic if  potent 
aromatase inhibition) and  inhibition of reproduction. 
Endocrine hazard profiles (wildlife)
● Case study conducted on 10 top selling EBIs in 
Germany (2009).
● Scientific literature and studies available from the 
EU review-process for active substances and 
from the German authorization procedure for 
plant protection products considered in analysis.
● Evidence for endocrine disrupting properties in-
vitro and for endocrine mediated adverse effects 
in-vivo (only mammals and fish) is summarized in 
the table below. 
● Proposal for differentiation in decision making: If 
endocrine disrupting properties are decisive for 
the overall hazard potential, the active substance 
should be considered an endocrine disruptor of 
regulatory concern in wildlife (i.e. cut-off applies).
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mammalian
studiesd)
in males↓ / in 
females ↑ , 
gestation length 
↑, parturition 
length ↑, con-
ception rate ↓, 
fertility index ↓, 
litter loss ↑ (ref. 
12, 16, 17)
distance ↑ in 
females, vaginal 
haemorrhages, 
impaired fertility, 
gestation length 
↑, dystocia (ref. 
13,15)
tal weight ↑, 
gestation length 
↑, dystocia (ref. 
12)
in males ↑, testis 
weight ↑ (ref. 12, 
14, 15)
↑, fertility↓, litter 
size↓ (ref. 12)
indications of 
endocrine 
disruption.“
anogenital dist-
ance ↑ in fe-
males, post-
implantation loss 
↑, litter size↓ (ref. 
12, 13, 15)
thyroid hormone 
levels ↓, litter size 
↓, dystocia, liver 
toxicity observed 
at lower doses 
than repro- and 
developmental 
effects
liver toxicity
observed at 
lower doses than 
repro- and 
developmental 
effects (ref. 12)
implantation 
survival ↓, 
teratogenic
effects observed 
at lower doses 
than repro-
effects
Evidence  for 
endocrine 
mediated 
(adverse) 
effects in-vivo: 
fish studiese)
Yes:
Vitellogenin in 
females ↓, shift in 
sex ratio to-
wards males, re-
production ↓
Yes:
Vitellogenin in 
males and fe-
males ↓, shift in 
sex ratio to-
wards males, re-
production ↓
Yes:
Vitellogenin in 
males and fe-
males ↓, sex ratio 
data unambigu-
ous, reproduc-
tion ↓
(No):
reproduction ↓ 
(study not state-
of-the-art regar-
ding endocrine 
specific  end-
points)
(Yes):
Vitellogenin in fe-
males ↓ (only 
screening study 
available, repro-
duction and sex 
ratio not asses-
sed)
(Yes):
indication for 
shift in sex ratio 
towards males 
and impaired 
reproductive 
performance at 
highest test conc.
(Yes):
yolk accumu-
lation in oocytes
↓, sexual mat-
urity ↓, reproduc-
tion ↓, liver cell 
degeneration 
most sensitive
(Yes):
indication for shift 
in sex ratio to-
wards males , re-
production ↓, mal-
formations in ELS 
study at clearly 
lower test conc.
(No):
endocrine scree-
ning study neg-
ative, FLC: re-
production ↓, in-
dication for
Vitellogenin ↓ in 
females
(No):
reproduction ↓ 
(Vitellogenin and 
sex ratio: poor 
data quality)
Acute-to-
chronic ratio 
fishf)
87
(reproduction, 
FLC) 
630
(reproduction, 
FLC) 
209
(reproduction, 
FLC) 
140
(growth, ELS)
596
(Vitellogenin,
FSA)
226
(growth males,
FLC)
724
(liver toxicity, 
FSDT)
1985
(malformations,
ELS)
118
(growth, ELS)
724
(growth, ELS)
BCF fishg) 393 59.8 205 116 21 30 78 65 35 129
Other aquatic 
organisms 
clearly more 
sensitive than 
fish?h)
No
(NOEC repro-
duction Daphnia
2.2 x lower)
No
(EC50 growth 
Lemna 1.4 x 
lower)
No
(NOEC repro-
duction Daphnia
134 x higher)
No
(NOEC repro-
duction Daphnia
5.7 x higher)
No
(NOEC repro-
duction Daphnia
3.3 x higher)
No
(NOEC repro-
duction Daphnia
1.5 x higher)
No
(NOEC repro-
duction Daphnia
1.7 x higher)
No
(EC50 growth 
green algae 22 x 
higher)
Yes
(NOEC repro-
duction Daphnia
7 x lower)
No
(NOEC repro-
duction Daphnia
55 x higher)
Are endocrine 
disrupting pro-
perties decisive 
for the overall 
hazard potential
in wildlife?
Please add your 
conclusion   
here ►
authors`
conclusion: 
Yes
your conclusion:
authors`
conclusion: 
Yes
your conclusion:
authors`
conclusion: 
Yes
your conclusion:
authors`
conclusion: 
Inconclusive
your conclusion:
authors`
conclusion: 
Inconclusive
your conclusion:
authors`
conclusion: 
Inconclusive
your conclusion:
authors`
conclusion: 
Inconclusive
your conclusion:
authors`
conclusion: 
No
your conclusion:
authors`
conclusion: 
No
your conclusion:
authors`
conclusion: 
No
your conclusion:
Table legend:
a) Reported by BVL (2009) – www.bvl.bund.de
b) Information from published papers only (reference numbers given in brackets).
c) Concentrations at half maximum inhibition (IC50 ) taken from Trösken et al. (2004), i.e. the in-vitro study where a maximum number of EBIs 
considered here have been comparatively studied under identical experimental conditions. 
d) Compiled from EFSA-Conclusions and/or Draft (Re)Assessment Reports for the active substances (tox sections) and published papers (refer-
ence numbers given in brackets).
e) Compiled from EFSA-Conclusions and/or Draft (Re)Assessment Reports for the active substances (ecotox sections) and/or original study reports 
available to UBA.
f) Acute-to-chronic-ratio (ACR) = Lethal concentration (LC50, mg/L) / No-observed-effect-concentration (NOEC, mg/L); the affected endpoint 
relevant for NOEC-derivation and study desgin is given in brackets. For studies without constant exposure, a calculation of time-weighted-
average exposure concentrations  for the suspected most sensitive life stage was conducted. Geometric mean values of LC50 for a warm and a 
cold water species (if available) used for calculation. Low-effect-concentrations (EC5 or EC10) from some studies derived as a surrogate for 
NOECs have been considered. ELS: early life stage study (without endocrine-specific endpoints). FLC: full-life-cycle study (state-of-the art FLC 
include endocrine specific endpoints like Vitellogenin-measurement, sex ratio determination, time-to-first-spawning, etc.). FSDT: fish-sexual-
development-test (sex ratio as endocrine specific core endpoint, Vitellogenin-measurement may be included). FSA: fish screening assay 
(indicative assay, no endocrine specific population-relevant endpoints included, Vitellogenin-measurement as endocrine specific core endpoint).
g) Bioconcentration factor (BCF, whole fish) determined in standard laboratory studies as reported in EFSA-Conclusions and/or Draft (Re)Assess-
ment Reports for the active substances.
h) Comparison with all other available acute and chronic single-species toxicity data for aquatic organisms tested in standard laboratory studies with 
constant exposure. Data taken from EFSA-Conclusions and/or Draft (Re)Assessment Reports for the active substances and/or UBA toxicity data 
base. Toxicity measure, endpoints and species for the next most sensitive aquatic organism given in brackets.
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